{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T05:33:39Z","timestamp":1786253619967,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008109","name":"Wuxi Municipal Bureau on Science and Technology","doi-asserted-by":"publisher","award":["K20231039"],"award-info":[{"award-number":["K20231039"]}],"id":[{"id":"10.13039\/501100008109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008109","name":"Wuxi Municipal Bureau on Science and Technology","doi-asserted-by":"publisher","award":["K20231049"],"award-info":[{"award-number":["K20231049"]}],"id":[{"id":"10.13039\/501100008109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104244"],"award-info":[{"award-number":["82104244"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jad.2025.04.087","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T12:41:22Z","timestamp":1745325682000},"page":"274-281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Analysis of risk signals for Viloxazine in the treatment of attention deficit hyperactivity disorder based on the FAERS database"],"prefix":"10.1016","volume":"382","author":[{"given":"Shuai","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuezheng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haohao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2025.04.087_bb0005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation[J]","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.jad.2025.04.087_bb0010","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management[J]","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf."},{"issue":"11","key":"10.1016\/j.jad.2025.04.087_bb0015","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1080\/14737175.2023.2265068","article-title":"Viloxazine extended-release capsules for the treatment of attention-deficit\/hyperactivity disorder in adult patients[J]","volume":"23","author":"Childress","year":"2023","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.jad.2025.04.087_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104769","article-title":"Half a century of research on attention-deficit\/hyperactivity disorder: a scientometric study[J]","volume":"140","author":"Cortese","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"3","key":"10.1016\/j.jad.2025.04.087_bb0025","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system[J]","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am. Stat."},{"key":"10.1016\/j.jad.2025.04.087_bb0030","article-title":"Viloxazine in the treatment of attention deficit hyperactivity disorder[J]","volume":"12","author":"Edinoff","year":"2021","journal-title":"Front. Psych."},{"issue":"6","key":"10.1016\/j.jad.2025.04.087_bb0035","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports[J]","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"2","key":"10.1016\/j.jad.2025.04.087_bb0040","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/JCP.0000000000001361","article-title":"Pharmacokinetics of coadministered viloxazine extended-release (SPN-812) and lisdexamfetamine in healthy adults[J]","volume":"41","author":"Faison","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.jad.2025.04.087_bb0045","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s40263-021-00825-w","article-title":"Viloxazine in the management of CNS disorders: a historical overview and current status[J]","volume":"35","author":"Findling","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2025.04.087_bb0050","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jad.2024.07.103","article-title":"Comprehensive analysis of adverse events associated with pimavanserin using the FAERS database[J]","volume":"362","author":"Gu","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"16","key":"10.1016\/j.jad.2025.04.087_bb0055","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1002\/hbm.25156","article-title":"Visual stimuli induce serotonin release in occipital cortex: a simultaneous positron emission tomography\/magnetic resonance imaging study[J]","volume":"41","author":"Hansen","year":"2020","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.jad.2025.04.087_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2020.109987","article-title":"Triple reuptake inhibition of serotonin, norepinephrine, and dopamine increases the tonic activation of \u03b12-adrenoceptors in the rat hippocampus and dopamine levels in the nucleus accumbens[J]","volume":"103","author":"Jiang","year":"2020","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2025.04.087_bb0065","first-page":"1","article-title":"The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database[J]","author":"Jiang","year":"2023","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.jad.2025.04.087_bb0070","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1038\/s41598-024-58460-6","article-title":"Analysis of post-market adverse events of istradefylline: a real-world study base on FAERS database[J]","volume":"14","author":"Jiang","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jad.2025.04.087_bb0075","article-title":"Unveiling the adverse events of Nusinersen in spinal muscular atrophy management based on FAERS database[J]","volume":"14","author":"Jiang","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jad.2025.04.087_bb0080","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s12888-024-05813-0","article-title":"Exploring adverse events of Vilazodone: evidence from the FAERS database[J]","volume":"24","author":"Jiang","year":"2024","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2025.04.087_bb0085","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","article-title":"Safety assessment of Brexpiprazole: real-world adverse event analysis from the FAERS database[J]","volume":"346","author":"Jiang","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.04.087_bb0090","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jad.2024.03.085","article-title":"Multidimensional assessment of adverse events of bupropion: a large-scale data analysis from the FAERS database[J]","volume":"354","author":"Lu","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.04.087_bb0095","doi-asserted-by":"crossref","first-page":"10029","DOI":"10.1039\/D4GC01957A","article-title":"Glycerol and its derivatives as potential C-3 bio-based building blocks for accessing active pharmaceutical ingredients[J]","volume":"26","author":"Morodo","year":"2024","journal-title":"Green Chem."},{"issue":"2","key":"10.1016\/j.jad.2025.04.087_bb0100","doi-asserted-by":"crossref","first-page":"43","DOI":"10.64719\/pb.4401","article-title":"A phase 3 placebo-controlled trial of once-daily 400-mg and 600-mg SPN-812 (viloxazine extended-release) in adolescents with ADHD[J]","volume":"51","author":"Nasser","year":"2021","journal-title":"Psychopharmacol. Bull."},{"issue":"8","key":"10.1016\/j.jad.2025.04.087_bb0105","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.14330","article-title":"Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended-release in children and adolescents with attention-deficit\/hyperactivity disorder[J]","volume":"75","author":"Nasser","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.jad.2025.04.087_bb0110","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.2147\/NDT.S312011","article-title":"The effect of viloxazine extended-release capsules on functional impairments associated with attention-deficit\/hyperactivity disorder (ADHD) in children and adolescents in four phase 3 placebo-controlled trials[J]","author":"Nasser","year":"2021","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"8","key":"10.1016\/j.jad.2025.04.087_bb0115","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s40263-022-00938-w","article-title":"A phase III, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of viloxazine extended-release capsules in adults with attention-deficit\/hyperactivity disorder[J]","volume":"36","author":"Nasser","year":"2022","journal-title":"CNS Drugs"},{"issue":"8","key":"10.1016\/j.jad.2025.04.087_bb0120","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio[J]","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.jad.2025.04.087_bb0125","doi-asserted-by":"crossref","DOI":"10.1177\/11795735221092522","article-title":"Viloxazine for attention-deficit hyperactivity disorder: a systematic review and meta-analysis of randomized clinical trials[J]","volume":"14","author":"Singh","year":"2022","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"10.1016\/j.jad.2025.04.087_bb0130","first-page":"11","article-title":"The prevalence of adult attention-deficit hyperactivity disorder: a global systematic review and meta-analysis[J]","author":"Song","year":"2021","journal-title":"J. Glob. Health"},{"key":"10.1016\/j.jad.2025.04.087_bb0135","series-title":"Seminars in Arthritis and Rheumatism","first-page":"1200","article-title":"Association between central nervous system stimulants used to treat attention deficit hyperactivity disorder (ADHD) and Raynaud\u2019s phenomenon: a scoping review[C]","volume":"51(6)","author":"Umair","year":"2021"},{"issue":"115\u2013125","key":"10.1016\/j.jad.2025.04.087_bb0140","article-title":"Predictors of changes in height, weight, and body mass index after initiation of central nervous system stimulants in children with attention deficit hyperactivity disorder[J]","volume":"241","author":"Waxmonsky","year":"2022","journal-title":"J. Pediatr."},{"key":"10.1016\/j.jad.2025.04.087_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-020-01585-y","article-title":"Guidance for identification and treatment of individuals with attention deficit\/hyperactivity disorder and autism spectrum disorder based upon expert consensus[J]","volume":"18","author":"Young","year":"2020","journal-title":"BMC Med."},{"key":"10.1016\/j.jad.2025.04.087_bb0150","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jad.2023.11.076","article-title":"Mining and analysis of adverse event signals of Cariprazine based on the real-world data of FAERS database[J]","volume":"347","author":"Zhu","year":"2024","journal-title":"J. Affect. Disord."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725006615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725006615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:41:18Z","timestamp":1778244078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032725006615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":30,"alternative-id":["S0165032725006615"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2025.04.087","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of risk signals for Viloxazine in the treatment of attention deficit hyperactivity disorder based on the FAERS database","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2025.04.087","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}